Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
Gui-Ming DengHai-Bin SongZhong-Ze DuYing-Wei XueHong-Jiang SongYuan-Zhou Li
Published in: World journal of gastroenterology (2024)
The presence of sarcopenia or myosteatosis is a reliable predictor of the clinical outcomes of patients with GC who are undergoing treatment with an ICI.